Lancet study: No statistically significant clinical benefits of remdesivir in COVID patients

Credit: Indian Express- Published on April 30, 2020

Video credit: Reuters Studio
Published on April 29, 2020 -  03:05
Data on Gilead drug raises hopes, Fauci calls it 'highly significant'
The top U.S. infectious disease official said Gilead Sciences Inc's experimental antiviral drug remdesivir will become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus. Yahaira Jacquez reports.

You are here

Related videos from verified sources

Chloroquine And Hydroxychloroquine Could Pose Higher COVID-19 Death Risk 00:35
Credit: Wochit - Published 2 weeks ago 


Related news from verified sources

India is part of the WHO ‘solidarity trials’ for the drug Remdesivir, which has shown encouraging results in serious Covid-19 patients needing enhanced...
on April 13, 2020 • IndiaTimes